Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study (original) (raw)

Abstract

Background and aims

Outcome data of sequential hepatitis B virus treatment with tenofovir alafenamide (TAF) are limited. We aimed to assess the effectiveness and renal safety of TAF in chronic hepatitis B (CHB) patients who were previously treated with entecavir (ETV), tenofovir disoproxil fumarate (TDF), or a nucleos(t)ide analogue (NA) combination.

Methods

This multicenter, retrospective, cohort study included 458 consecutive CHB patients who switched to TAF monotherapy after at least 2 years of treatment with another NA. The longitudinal virological/laboratory responses were evaluated up to 96 weeks after switchover. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2.

Results

The proportions of complete viral suppression (CVS) (HBV DNA < 20 IU/mL) at week 96 were 99.0%, 98.5%, and 98.4% in the prior ETV (n = 198), TDF (n = 137), and NA combination (n = 123) groups, respectively. Almost all patients with HBV DNA of 20–2000 IU/mL at baseline achieved CVS at week 96. On multivariable generalized estimated equation analysis, a low quantitative hepatitis surface antigen (qHBsAg) level at baseline was associated with a lower follow-up qHBsAg level (coefficient 0.81, p < 0.001). The eGFR showed greater improvement in patients with CKD compared to those without (coefficient 21.7, p < 0.001). However, the increase of eGFR reached a peak between weeks 24 and 48.

Conclusions

Based on this longitudinal data analysis up to 96 weeks, sequential NA therapy with a switch to TAF is a good option to achieve high viral suppression and renal safety.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

AASLD:

American Association for the Study of Liver Diseases

ADF:

Adefovir

ALT:

Alanine aminotransferase

BMI:

Body mass index

CHB:

Chronic hepatitis B

CI:

Confidence interval

CKD:

Chronic kidney disease

CVS:

Complete viral suppression

eGFR:

Estimated glomerular filtration rate

ETV:

Entecavir

GEE:

Generalized estimating equation

HBeAg:

Hepatitis B e antigen

HBsAg:

Hepatitis B surface antigen

HBV:

Hepatitis B virus

HCC:

Hepatocellular carcinoma

HIV:

Human immunodeficiency virus

LAM:

Lamivudine

NA:

Nucleos(t)ide analogue

qHBsAg:

Quantitative hepatitis B surface antigen

TAF:

Tenofovir alafenamide

TDF:

Tenofovir disoproxil fumarate

References

  1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128
    Article PubMed Google Scholar
  2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555
    Article PubMed Google Scholar
  3. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599
    Article PubMed Google Scholar
  4. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398
    Article Google Scholar
  5. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98
    Article CAS PubMed Google Scholar
  6. Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. J Hepatol. 2017;67:847–861
    Article PubMed Google Scholar
  7. Cornberg M, Lok AS, Terrault NA, Zoulim F. EASL-AASLD HBV treatment endpoints conference faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B—report from the 2019 EASL-AASLD HBV treatment endpoints conference‡. J Hepatol. 2019;2020(72):539–557
    Google Scholar
  8. Ogawa E, Furusyo N, Nguyen MH. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. Drug Des Devel Ther. 2017;11:3197–3204
    Article CAS PubMed PubMed Central Google Scholar
  9. Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63:284–306
    Article CAS PubMed Google Scholar
  10. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139:1218–1229
    Article CAS PubMed Google Scholar
  11. Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319:1802–1813
    Article CAS PubMed Google Scholar
  12. Casado JL. Renal and bone toxicity with the use of tenofovir: understanding at the end. AIDS Rev. 2016;18:59–68
    PubMed Google Scholar
  13. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60:1457–1464
    Article CAS PubMed Google Scholar
  14. Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185–195
    Article PubMed Google Scholar
  15. Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196–206
    Article PubMed Google Scholar
  16. Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672–681
    Article CAS PubMed Google Scholar
  17. Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40:1578–1589
    Article CAS PubMed Google Scholar
  18. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–992
    Article CAS PubMed Google Scholar
  19. Ogawa E, Furusyo N, Murata M, Ohnishi H, Toyoda K, Taniai H, et al. Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. Hepatol Res. 2011;41:1178–1188
    Article CAS PubMed Google Scholar
  20. Uchida Y, Nakao M, Tsuji S, Uemura H, Kouyama JI, Naiki K, et al. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate. J Med Virol. 2020;92:329–338
    Article CAS PubMed Google Scholar
  21. Li ZB, Li L, Niu XX, Chen SH, Fu YM, Wang CY, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int. 2021;41:1254–1264
    Article CAS PubMed Google Scholar
  22. Nguyen MH, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh HN, et al. Outcomes of sequential therapy with tenofovir alafenamide after long-term entecavir. Am J Gastroenterol. 2021;116:1264–1273
    Article PubMed Google Scholar
  23. Fong TL, Lee BT, Tien A, Chang M, Lim C, Ahn A, et al. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. J Viral Hepat. 2019;26:561–567
    Article CAS PubMed Google Scholar
  24. Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5:441–453
    Article PubMed Google Scholar
  25. Toyoda H, Leong J, Landis C, Atsukawa M, Watanabe T, Huang DQ, et al. Treatment and renal outcomes up to 96 weeks after tenofovir alafenamide switch from tenofovir disoproxil fumarate in routine practice. Hepatology. 2021. https://doi.org/10.1002/hep.31793
    Article PubMed Google Scholar
  26. Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537–1547
    Article CAS PubMed Google Scholar
  27. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140–1149
    Article CAS PubMed Google Scholar
  28. Yip TC, Wong GL, Chan HL, Tse YK, Lam KL, Lui GC, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70:361–370
    Article CAS PubMed Google Scholar
  29. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50:1–3
    Article PubMed Google Scholar
  30. Razek AA, Abdalla A, Omran E, Fathy A, Zalata K. Diagnosis and quantification of hepatic fibrosis in children with diffusion weighted MR imaging. Eur J Radiol. 2011;78:129–134
    Article PubMed Google Scholar
  31. Razek AAKA, Khashaba M, Abdalla A, Bayomy M, Barakat T. Apparent diffusion coefficient value of hepatic fibrosis and inflammation in children with chronic hepatitis. Radiol Med. 2014;119:903–909
    Article PubMed Google Scholar
  32. Razek AA, Massoud SM, Azziz MR, El-Bendary MM, Zalata K, Motawea EM. Prediction of esophageal varices in cirrhotic patients with apparent diffusion coefficient of the spleen. Abdom Imaging. 2015;40:1465–1469
    Article PubMed Google Scholar
  33. Besheer T, Elalfy H, Abd El-Maksoud M, Abd El-Razek A, Taman S, Zalata K, et al. Diffusion-weighted magnetic resonance imaging and micro-RNA in the diagnosis of hepatic fibrosis in chronic hepatitis C virus. World J Gastroenterol. 2019;25:1366–1377
    Article CAS PubMed PubMed Central Google Scholar
  34. Surial B, Mugglin C, Calmy A, Cavassini M, Günthard HF, Stöckle M, et al. Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study. Ann Intern Med. 2021. https://doi.org/10.7326/M20-4853
    Article PubMed Google Scholar
  35. Chan HLY, Buti M, Agarwal K, et al. Maintenance of high levels of viral suppression and improved safety profile of tenofovir alafenamide relative to tenofovir disoproxil fumarate in chronic hepatitis B patients treated for 5 years in 2 ongoing phase 3 studies. Hepatology. 2020;72:490A
    Google Scholar
  36. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49:S185–S195
    Article CAS PubMed Google Scholar
  37. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:941–946
    Article PubMed Google Scholar
  38. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278–285
    Article CAS PubMed Google Scholar
  39. Tamaki N, Kurosaki M, Nakanishi H, Itakura J, Inada K, Kirino S, et al. Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B. J Med Virol. 2020;92:1355–1358
    Article CAS PubMed Google Scholar

Download references

Funding

This study was funded by Gilead Sciences.

Author information

Authors and Affiliations

  1. Department of General Internal Medicine, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan
    Eiichi Ogawa
  2. Department of Gastroenterology, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan
    Makoto Nakamuta & Naoki Yamashita
  3. Department of Medicine, Fukuoka City Hospital, Fukuoka, Japan
    Toshimasa Koyanagi
  4. Department of Hepatology, Steel Memorial Yawata Hospital, Kitakyushu, Japan
    Aritsune Ooho
  5. General Internal Medicine, Taihaku Avenue Clinic, Fukuoka, Japan
    Norihiro Furusyo
  6. Kajiwara Clinic, Kitakyushu, Japan
    Eiji Kajiwara
  7. Department of Internal Medicine, Chihaya Hospital, Fukuoka, Japan
    Kazufumi Dohmen
  8. Department of Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
    Akira Kawano
  9. Center for Liver Disease, Kokura Medical Center, National Hospital Organization, Kitakyushu, Japan
    Takeaki Satoh
  10. Department of Medicine, Hamanomachi Hospital, Fukuoka, Japan
    Kazuhiro Takahashi
  11. Department of Medicine, Kyushu Central Hospital, Fukuoka, Japan
    Koichi Azuma
  12. The Center for Liver Disease, Shin-Kokura Hospital, Kitakyushu, Japan
    Nobuyuki Yamashita
  13. Department of Gastroenterology, Kyushu Cancer Center, Fukuoka, Japan
    Rie Sugimoto
  14. Amagase Clinic, Kitakyushu, Japan
    Hiromasa Amagase
  15. Department of Gastroenterology, Kyushu Rosai Hospital, Kitakyushu, Japan
    Masami Kuniyoshi
  16. Department of Internal Medicine, JCHO Kyushu Hospital, Kitakyushu, Japan
    Yasunori Ichiki
  17. Department of Internal Medicine, Kyushu Railway Memorial Hospital, Kitakyushu, Japan
    Chie Morita
  18. Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Masaki Kato
  19. Graduate School of Nutritional Sciences, Nakamura Gakuen University, Fukuoka, Japan
    Masaki Kato
  20. Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Shinji Shimoda
  21. Department of Internal Medicine, Haradoi Hospital, Fukuoka, Japan
    Hideyuki Nomura
  22. Kyushu General Internal Medicine Center, Haradoi Hospital, Fukuoka, Japan
    Jun Hayashi

Authors

  1. Eiichi Ogawa
  2. Makoto Nakamuta
  3. Toshimasa Koyanagi
  4. Aritsune Ooho
  5. Norihiro Furusyo
  6. Eiji Kajiwara
  7. Kazufumi Dohmen
  8. Akira Kawano
  9. Takeaki Satoh
  10. Kazuhiro Takahashi
  11. Koichi Azuma
  12. Nobuyuki Yamashita
  13. Naoki Yamashita
  14. Rie Sugimoto
  15. Hiromasa Amagase
  16. Masami Kuniyoshi
  17. Yasunori Ichiki
  18. Chie Morita
  19. Masaki Kato
  20. Shinji Shimoda
  21. Hideyuki Nomura
  22. Jun Hayashi

Consortia

The Kyushu University Liver Disease Study (KULDS) Group

Contributions

All authors were involved in the design of the study, acquisition of samples and/or analysis. EO drafted the manuscript. All authors contributed to the critical discussion of the results and approved the final version of the article.

Corresponding author

Correspondence toEiichi Ogawa.

Ethics declarations

Conflict of interest

Eiichi Ogawa has received speaker fees from Gilead Sciences and AbbVie. Makoto Nakamuta, Toshimasa Koyanagi, Aritsune Ooho, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Takeaki Satoh, Kazuhiro Takahashi, Koichi Azuma, Nobuyuki Yamashita, Naoki Yamashita, Rie Sugimoto, Hiromasa Amagase, Masami Kuniyoshi, Yasunori Ichiki, Chie Morita, Masaki Kato, Shinji Shimoda, Hideyuki Nomura, and Jun Hayashi declare that they have no conflicts of interest.

Ethical approval

The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the STROBE statement. It was approved by the Ethics Committees of Kyushu University Hospital and each study site and is registered as a clinical study on the University Hospital Medical Information Network (ID 000034696).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

About this article

Cite this article

Ogawa, E., Nakamuta, M., Koyanagi, T. et al. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.Hepatol Int 16, 282–293 (2022). https://doi.org/10.1007/s12072-021-10295-3

Download citation

Keywords